By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galapagos NV 

Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
Mechelen    B-2800  Belgium
Phone: 32-15-34-29-00 Fax: 32-15-34-29-01



Company News
Galapagos (GLPG.BR) Release: Endoscopic Improvements With Filgotinib Are Consistent With Clinical Remission Rates In Patients With Crohn's Disease 9/26/2016 9:36:44 AM
Galapagos (GLPG.BR) Increases Share Capital Through Warrant Exercises 9/20/2016 9:08:50 AM
Galapagos (GLPG.BR) Release: Orphan Drug Designation In European Union For GLPG1690 In Idiopathic Pulmonary Fibrosis 9/6/2016 2:30:51 PM
Galapagos (GLPG.BR) Release: Finch Filgotinib Phase 3 Program Initiated In Rheumatoid Arthritis 8/23/2016 8:49:34 AM
Galapagos (GLPG.BR) Receives Transparency Notification From Federated 8/1/2016 9:27:33 AM
Invitation To The Special And Extraordinary Shareholders' Meetings Of 26 July 2016 - Nomination Of Mary Kerr For Galapagos (GLPG.BR)' Board of Directors 6/23/2016 9:18:50 AM
Galapagos (GLPG.BR) Selected For AEX Index 6/9/2016 12:41:20 PM
Galapagos (GLPG.BR) Creates New Warrant Plan 6/2/2016 8:26:35 AM
Galapagos (GLPG.BR) Release: FITZROY Phase 2 Study With Filgotinib In Crohn's Disease Presented As Late Breaker At DDW 2016 5/26/2016 9:40:41 AM
Galapagos (GLPG.BR) Release: Successful Completion Of End-Of-Phase 2 FDA And European Medicines Agency Consultations In Rheumatoid Arthritis (RA) 5/25/2016 9:15:56 AM